Suraksha Diagnostic Limited files DRHP with SEBI

Suraksha Diagnostic Limited, the largest full-service and integrated diagnostic chain headquartered in east India, in terms of operating income as of Fiscal 2023 as per a CRISIL Report, has filed the draft red herring prospectus (DRHP) with capital markets regulator SEBI to float an initial public offering (IPO). 

According to the draft red herring prospectus, the Initial Public Offering of the Kolkata headquartered company consists of an Offer for Sale of up to 19,189,330 Equity Shares by the Selling Shareholders. 

The OFS comprises of up to 10,660,737 Equity Shares by the Investor Selling Shareholder - OrbiMed Asia II Mauritius Limited; up to 2,132,148 Equity Shares each by the Promoter Selling Shareholders - Dr. Somnath Chatterjee, Ritu Mittal and Satish Kumar Verma, and the Individual Selling Shareholders, Munna Lal Kejriwal and Santosh Kumar Kejriwal offering up to 799,556 Equity Shares and up to 1,332,593 Equity Shares, respectively. 

The objects of the Offer are to carry out the Offer for Sale of up to 19,189,330 Equity Shares by the Selling Shareholders; and achieve the benefits of listing the Equity Shares on the Stock Exchanges. 

Dr. Somnath Chatterjee along with late Kishan Kumar Kejriwal built a fully comprehensive diagnostic centre in Kolkata, under the ‘Suraksha’ brand in 1992. The company which is currently promoted by Dr. Somnath Chatterjee, Joint Managing Director, and Ritu Mittal, Joint Managing Director and Chief Executive Officer offers a one-stop integrated solution for pathology and radiology testing, and medical consultation services to its customers through its extensive operational network, consisting of a flagship central reference laboratory, 8 satellite laboratories (co-located with diagnostic centers) and 194 customer touchpoints which include 48 diagnostic centres, and 146 sample collection centres (primarily franchised), across the states of West Bengal, Bihar, Assam, and Meghalaya, as of March 31, 2024. 

Suraksha offers a comprehensive range of 2,300+ tests that cover a range of specialties and disciplines. 

During Fiscal 2024, it conducted approximately 5.98 million tests serving approximately 1.14 million patients. 

ICICI Securities Limited, Nuvama Wealth Management Limited and SBI Capital Markets Limited are the book running lead managers to the issue. The equity shares are proposed to be listed on BSE and NSE.

Comments

Post a Comment

Popular posts from this blog

First DPL match was won by US Consulate Staff Team

Image
  ICWO - Indian Community Welfare Organisation  organized the First DPL- Diplomat Cricket Tournament for Embassy, Consulate & High Commission Staff on 10 th   August 2024 at Soka Ikeda College of Arts and Science for Women, Sethu Bhaskara Nagar, Madhanangkuppam, Kolathur, Chennai. T he event aims to create high level Awareness to STOP Child Abuse, Child Trafficking, Child Marriage & Child Labour in Tamilnadu and mobilize funds for intervention to address the same. A.J.Hariharan, Secretary – ICWO thanked both the US Consulate and Malaysian Consulate for their support and participation in the diplomate cricket tournament as to create an awareness about the Child Marriage, Child Trafficking & Child Labour and Child Abuse in Tamilnadu. The tournament has created huge interest among the players and the consul officials. We, ICWO have plan to organize similar event on 3 rd  May 2025. This time for men and women doubles badminton tournament. We emphasis there is...
Read more

TATA AIG Strengthens Tamil Nadu Health Insurance Portfolio with New Riders amid Strong Growth

Image
Chennai, 12 November 2024: TATA AIG General Insurance, a leading general insurance provider in India, is strengthening its health insurance offerings in Tamil Nadu with five specialised riders: Mental Wellbeing, Empower Her, OPD Care, CanCare, and Flexi Shield. These riders are specifically designed to address the unique and diverse healthcare needs of the state’s residents, providing enhanced protection in areas such as mental health, women’s health, cancer treatment, and routine medical costs. TATA AIG has established a robust presence across 31 districts in Tamil Nadu, with key branches in Chennai, Coimbatore, Madurai, Tiruchirapalli, Tirunelveli, and Salem. The company’s expansive network includes over 1000 hospitals, ensuring seamless access to cashless treatment for its customers across both urban and rural regions. With a well-established network of agents and digital platforms, the company is bringing quality health insurance solutions to every corner of the state. This pe...
Read more

Apollo Cancer Centers now introduces Made in India, CAR T Cell Program

Image
First Private Hospital in India to Successfully Complete CAR T Cell Therapy.  In a ground-breaking development, Apollo Cancer Centres (ACCs) has emerged as the first private hospital group in India to have a successfully complete CAR-T cell program and to further augment it, the group will now provide access to Made in India CAR-T cell therapy, beginning with NexCAR19 (Actalycabtagene autoleucel), for the treatment of B-cell lymphomas and B-acute lymphoblastic leukaemia in patients aged 15 years and above.   Marking a historic moment in the country's medical landscape , Dr. T Raja, Director of Medical Oncology at ACC, Chennai, spearheaded the development of this revolutionary clinical program, and has successfully treated six patients till date.   CAR-T cell therapies, often known as living drugs involve the extraction of a patients T-cells (a type of white blood cells whose function is to fight cancer cells) through a process known as Apheresis. These T-cells are t...
Read more